Table 7.
Continuing and finished clinical trials of liposome-based formulations evaluated for ocular delivery.
| Clinical Trials | Indication | Phase | Enrolment | Identifier |
|---|---|---|---|---|
| Subconjunctival treatment of liposomal sirolimus as a treatment for dry eye disease. Ocular surface disease index is examined on a scale of 0 to 100, with the highest scores representing greater disability | Dry eye disease | Phase I | 52 | NCT04115800 |
| Safety and therapeutic effect of liposomal latanoprost in ocular hypertension. Subconjunctival injection of liposomal latanoprost with subjects that have raised intraocular pressure and monitored for pain, inflammation, and toxicity up to 3 months | Ocular hypertension | Phase 1 and 2 | 6 | NCT01987323 |
| Determine the 12-month event-free survival of pediatric patients’ eyes with group D intraocular retinoblastoma treated with systemic chemotherapy, subtenon carboplatin, and local ophthalmic treatment | Intraocular retinoblastoma | Phase 3 | 30 | NCT00072384 |
| Assess the therapeutic potential of a liposomal ozone-based solution (OZODROP®) in the preparation of the patient for cataract surgery, by evaluating the reduction of bacterial colonization of the conjunctiva | Ocular infections | Phase 4 | 200 | NCT04087733 |
| TLC399 (ProDex) was studied in participants with macular edema caused by central retinal vein blockage or branch retinal vein occlusion in a randomized, double-masked experiment | Retinal vein occlusion and macula edema | Phase 2 | 31 | NCT03093701 |
| Randomized interventional study wherein Aquoral Forte® was evaluated against Aquoral Lipo® (Cross-linked hyaluronic acid with liposomes and crocin) in dry eye | Dry eye disease is caused by moderate meibomian glands dysfunction | Not applicable | 25 | NCT03617315 |
| The safety and efficacy of subconjunctival liposomal latanoprost (POLAT-001) vs. latanoprost ophthalmic solution in patients were compared in an open-label, randomized, multi-center, active-controlled parallel study | Ocular hypertension and primary open-angle glaucoma | Phase 2 | 80 | NCT02466399 |
| Randomized interventional trials to evaluate the clinical efficacy of various categories of artificial tears in patients suffering from dry eyes by instilling each category of treatment (0.40% Sodium Hyaluronate (Clinitas Soothe), 0.15% Sodium Hyaluronate (Hyabak), 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears), and Phospholipid liposomal spray (Tears Again)) for a month and examined their tear film and ocular surface after each one | Dry eye | Not applicable | 80 | NCT02420834 |